Ocugen (OCGN) Income from Continuing Operations (2014 - 2026)
Ocugen's (OCGN) quarterly Income from Continuing Operations came in at 35859000.0 in Q1 2026, down 131.98% YoY from 112140081.33 in Q1 2025, and down 98.84% on a QoQ basis from 18034000.0 in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Income from Continuing Operations data on file, last reported at 35859000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 131.98% year-over-year to 35859000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92767000.0 (down 46.4% YoY) and the FY2025 annual result came in at 198039000.0, down 14.43% from the prior year.
- Income from Continuing Operations fell to 35859000.0 in Q1 2026, from 18034000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12981000.0 in Q3 2024 to a low of 123938000.0 in Q4 2023.
- A 5-year average of 27698411.76 and a median of 20985000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 464.92% — and 2024, when it jumped 88.75%.
- Tracing OCGN's Income from Continuing Operations over 5 years: stood at 21939000.0 in 2022, then tumbled by 464.92% to 123938000.0 in 2023, then jumped by 88.75% to 13941000.0 in 2024, then declined by 29.36% to 18034000.0 in 2025, then slumped by 98.84% to 35859000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 35859000.0 (Q1 2026), 18034000.0 (Q4 2025), and 18732000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -20.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.52 Mn |
| Mar 31, 2026 | -19.03 Mn |
| Dec 31, 2025 | -18.21 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -14.85 Mn |
| Mar 31, 2025 | -15.42 Mn |
| Dec 31, 2024 | -13.98 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -15.28 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |